The shares of Aduro BioTech, Inc. (NASDAQ:ADRO) has been pegged with a rating of Perform by Oppenheimer in its latest research note that was published on June 3rd, 2019. Oppenheimer wasn’t the only research firm that published a report of Aduro BioTech, Inc., with other equities research analysts also giving their opinion on the stock. SVB Leerink advised investors in its research note published on April 15th, 2019, to Outperform the ADRO stock while also putting a $9 price target. The stock had earned Overweight rating from Cantor Fitzgerald when it published its report on February 22nd, 2018. That day the Cantor Fitzgerald set price target on the stock to $15. The stock was given Buy rating by H.C. Wainwright in its report released on December 13th, 2017, the day when the price target on the stock was placed at $9.50. Rodman & Renshaw was of a view that ADRO is Buy in its latest report on May 1st, 2017 while giving it a price target of $18. FBR Capital thinks that ADRO is worth Outperform rating. This was contained in the firm’s report on May 17th, 2016 in which the stock’s price target was also moved to $22.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $7.00. The price of the stock the last time has raised by 8.20% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 42.55.
The shares of the company dipped by -3.65% during the trading session on Tuesday, reaching a low of $1.25 while ending the day at $1.32. During the trading session, a total of 2.01 million shares were traded which represents a -447962.98% decline from the average session volume which is 448.11K shares. ADRO had ended its last session trading at 1.37. Aduro BioTech, Inc. currently has a market cap of $110.60M while its P/E earnings growth sits at 7.58, with a beta of 1.41. Aduro BioTech, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 8.40. ADRO 52-week low price stands at $1.22 while its 52-week high price is $8.10.
The company in its last quarterly report recorded -$0.23 earnings per share which is below the -$0.18 predicted by most analysts. The Aduro BioTech, Inc. generated $4.89 million in revenue during the last quarter, which is slightly lower than the $10.07 million predicted by analysts. In the second quarter last year, the firm recorded -$0.29 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -26.09%. Aduro BioTech, Inc. has the potential to record -1.15 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Tudor Pickering published a research note on August 2nd, 2019 where it informed investors and clients that Cabot Oil & Gas Corporation (NYSE:COG) is now rated as Buy. Their price target on the stock stands at $25. SVB Leerink also rated COG as Initiated on April 15th, 2019, with its price target of $2 suggesting that COG could surge by 32.09% from its current share price. Even though the stock has been trading at $17.35/share, analysts expect it to surge higher by -2.07% to reach $25.02/share. It started the day trading at $17.57 and traded between $16.98 and $16.99 throughout the trading session.
A look at its technical shows that COG’s 50-day SMA is 22.10 while its 200-day SMA stands at 24.42. The stock has a high of $27.65 for the year while the low is $16.82. The company’s P/E ratio currently sits at 8.81, while the P/B ratio is 3.06. At the moment, only of Cabot Oil & Gas Corporation shares were sold short. The company’s average trading volume currently stands at 7.17M shares, which means that the short-interest ratio is just 3.19 days. Over the past seven days, the company moved, with its shift of -1.74%. Looking further, the stock has dropped -35.40% over the past 90 days while it lost -31.24% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more COG shares, increasing its portfolio by +3.55% during the last quarter. This move now sees The Vanguard Group Inc purchasing 1,631,839 shares in the last quarter, thus it now holds 47,624,893 shares of COG, with a total valuation of $912,492,950. SSgA Funds Management Inc meanwhile sold more COG shares in the recently filed quarter, changing its stake to $437,458,668 worth of shares. BlackRock Fund Advisors followed the path by decreasing its COG portfolio by -1.64% in the quarter. This means that BlackRock Fund Advisors sold -349,171 shares in the last quarter and now controls 20,957,317 shares of the COG stock, with the valuation hitting $401,542,194.
Similarly, Capital Research Management Co decreased its Cabot Oil & Gas Corporation shares by -68.77% during the recently filed quarter. After selling -33,579,606 shares in the last quarter, the firm now controls 15,246,904 shares of Cabot Oil & Gas Corporation which are valued at $292,130,681. In the same vein, Fidelity Management Research Co decreased its Cabot Oil & Gas Corporation shares by during the most recent reported quarter. The firm sold -1,112,395 shares during the quarter which decreased its stakes to 14,451,646 shares and is now valued at $276,893,537. Following these latest developments, around 1.70% of Cabot Oil & Gas Corporation stocks are owned by institutional investors and hedge funds.